We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Legal & General Group Plc | LSE:LGEN | London | Ordinary Share | GB0005603997 | ORD 2 1/2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
2.70 | 1.08% | 253.10 | 254.10 | 254.20 | 254.80 | 251.90 | 252.00 | 19,640,625 | 16:35:19 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Ins Agents,brokers & Service | 36.48B | 457M | 0.0764 | 33.29 | 15.21B |
TIDMIMM TIDMLGEN
RNS Number : 8768Z
Immupharma PLC
20 March 2017
20 MARCH 2017
NOTIFICATION OF MAJOR INTEREST BY LEGAL & GENERAL
ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that it has received notification by Legal & General Group Plc ("L&G") confirming its holding in ImmuPharma of 4,446,545 million Ordinary Shares in the capital of the Company, representing 3.35% of ImmuPharma's total voting rights figure of 132,522,985 Ordinary Shares.
Commenting, Tim McCarthy, Chairman of ImmuPharma, said: "We are delighted to be able to disclose Legal & General's increased holding in ImmuPharma as one of our existing major institutional investors which participated in our recent successful GBP4.1 million fundraising demonstrating its continued support for ImmuPharma."
Full disclosure of the TR1 is shown below:
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES ----------------------------------------------- 1. Identity of the issuer or ImmuPharma Plc the underlying issuer of existing shares to which voting rights are attached: ------------------------------------------------------------ ----------------------------- 2. Reason for the notification (please tick the appropriate box or boxes): ------------------------------------------------------------------------------------------- An acquisition or disposal of voting rights Yes --------------------------------------------------------------- -------------------------- An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached. --------------------------------------------------------------- -------------------------- An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments --------------------------------------------------------------- -------------------------- An event changing the breakdown of voting rights --------------------------------------------------------------- -------------------------- Other (please specify): -------------------------------------------------------- ----- -------------------------- 3. Full name of person(s) Legal & General Group Plc subject to the (L&G) notification obligation: ---------------------------------------------------------- ------------------------------- 4. Full name of shareholder(s) Legal & General Assurance (if different from 3.): Society Limited (LGAS) ---------------------------------------------------------- ------------------------------- 16 March 2017 5. Date of the transaction and date on which the threshold is crossed or reached: ---------------------------------------------------------- ------------------------------- 6. Date on which issuer 17 March 2017 notified: ---------------------------------------------------------- ------------------------------- 7. Threshold(s) that is/are L&G (Above 3%) crossed or reached: ---------------------------------------------------------- ------------------------------- 8. Notified details: ---------------------------------------------------------------------------------------------------------- A: Voting rights attached to shares ---------------------------------------------------------------------------------------------------------- Class/type Situation Resulting situation after the of previous triggering transaction shares to the triggering transaction if possible using the ISIN CODE ------------- ------------------------------- ---------------------------------------------------------- Number Number Number of voting % of voting of of rights rights Shares Voting Rights ------------- --------------- -------------- ------------ ----------------------- ------------------- Number Direct Indirect Direct Indirect of shares ------------- ------------- ------------- ------------ ----------- ---------- -------- --------- ORD GBP 0.10 Below 3% 4,446,545 4,446,545 - 3.35% - ------------- ------------------------------- ------------ ----------- ---------- -------- --------- B: Qualifying Financial Instruments ---------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ---------------------------------------------------------------------------------------------------------- Number of voting Type of Expiration Exercise/ rights that % of voting financial date Conversion may be rights instrument Period acquired if the instrument is exercised/ converted. --------------- -------------- --------------------------- ----------------------- ------------------- C: Financial Instruments with similar economic effect to Qualifying Financial Instruments ---------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ---------------------------------------------------------------------------------------------------------- Type of Exercise Expiration Exercise/ Number of voting % of voting financial price date Conversion rights instrument rights instrument period refers to -------------- -------------- -------------- ------------ ----------------------- ------------------- Nominal Delta -------------- -------------- -------------- ------------ ----------------------- -------- --------- Total (A+B+C) ---------------------------------------------------------------------------------------------------------- Number of voting rights Percentage of voting rights ------------------------------------------------------------ -------------------------------------------- (L&G) 4,446,545 3.35% ------------------------------------------------------------ -------------------------------------------- 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: ------------------------------------------------------------------------------------------ Legal & General Group Plc (Direct and Indirect) (Group) ( Below 5% = Total Position) Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect) ( Below 5% = Total Position) Legal & General Investment Management Limited (Indirect) (LGIM) ( Below 5% = Total Position) Legal & General Group Plc (Direct) (L&G) ( 4,446,545 -3.35% = LGAS,& PMC) Legal & General Investment Management Legal & General Insurance Holdings Limited (Holdings) Limited (Direct) (LGIMHD) (Direct) (LGIH) Legal & General Assurance (Pensions Legal & General Assurance Society Limited Management) Limited (PMC) (LGAS) Proxy Voting: ---------------------------------------------------------------------------- 10. Name of the proxy holder: N/A ------------------------------------- ------------------------------------- 11. Number of voting rights proxy N/A holder will cease to hold: ------------------------------------- ------------------------------------- 12. Date on which proxy holder will N/A cease to hold voting rights: ------------------------------------- -------------------------------------
Notification using the total 13. Additional information: voting rights figure of 132,522,985 ------------------------------------- ------------------------------------- 14. Contact name: Victoria Davies (LGIM) ------------------------------------- ------------------------------------- 15. Contact telephone number: 029 2035 4147 ------------------------------------- -------------------------------------
-Ends-
For further information please contact: + 44 (0) 20 ImmuPharma plc (www.immupharma.org) 7152 4080 Tim McCarthy, Chairman Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 Twitter: @immupharma 413496 Northland Capital Partners Limited (NOMAD & Broker) Patrick Claridge, David Hignell, Michael Mackintosh, Corporate Finance +44 (0)20 3861 Rob Rees, Corporate Broking 6625
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLLKLFFDXFZBBB
(END) Dow Jones Newswires
March 20, 2017 03:01 ET (07:01 GMT)
1 Year Legal & General Chart |
1 Month Legal & General Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions